Business Wire

MYbank Unveils Five-Year Plan to Reach More SMEs Across China via Supply Chain Finance and Rural Lending

30.6.2020 13:20:00 EEST | Business Wire | Press release

Share

MYbank, a leading online private commercial bank under Ant Group, today announced a five-year plan to reach more small and micro enterprises (SMEs) across China via supply chain finance and rural lending.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630005465/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The number of SMEs served by MYbank increased more than tenfold in five years (Graphic: Business Wire)

The five-year plan details MYbank’s aspirations to work with partners across multiple sectors to better serve SMEs across China. Key measures and initiatives MYbank will implement as part of the plan include:

  • Leveraging supply chain finance to support 10 million SMEs who traditionally have been unserved or underserved in the market.
  • Working with 2,000 county and village managers to provide rural lending to SMEs in need.
  • Collaborating with financial institution partners to distribute interest-free vouchers for business loans totaling RMB 300 billion.
  • Serving 40 million female business owners and providing them with more economic opportunities.

“Through this five-year plan, we look forward to working with more financial institution partners to realize our shared vision to make financial services more accessible for SMEs,” said Xiaolong Jin, President of MYbank. “In the past, SMEs had to go through a one-way application approval process when they came to us for lending services. By working with our partners and embedding our services seamlessly into use cases such as supply chain finance and rural lending, we hope to bring our services to SMEs across a wide spectrum of industries.”

Established on June 25, 2015, MYbank is one of the leading private online commercial banks in China focused on serving SMEs and farmers. It was the first bank in China to establish its core banking system entirely on the cloud without any physical branches. Leveraging Ant Group’s AI, computing and risk management technologies, MYbank also pioneered the “310 model” for SME financing, which offers collateral-free business loans that take less than three minutes to apply for on a mobile phone, less than one second to approve, and requires zero human intervention. SMEs in China supported by the “310 model” have shown resilience during the COVID-19 pandemic, with 98% of them repaying their loans on time.

According to data from the People’s Bank of China (PBOC), SMEs account for over 90% of business entities in China and contribute to 80% of urban employment and 60% of Chinese GDP. As of June 2020, MYbank and its partners have served 29 million SMEs in China, including street vendors. Their average loan size is RMB 36,000 (approximately USD$5,000) and 80% of them had previously never received business loans from a bank.

Leveraging Ant Group’s blockchain technology, Log56.com, a Chinese logistics platform with 70,000 registered corporate users, has helped 200,000 truck drivers and micro logistics business owners successfully apply for loans from MYbank and its financial institutional partners. Ant’s blockchain technology helped to ensure key logistics information, such as order and execution numbers, are tamper-proof. This also reduced costs related to risk management and helped MYbank’s AI to calculate an accurate line of credit for SME operators on the platform.

Jinmailang Food, a Chinese food manufacturing company, has over 5,000 distributors across its supply chain. Many of these distributors had to suspend their operations during the COVID-19 pandemic. To help these distributors cope with the economic impact of the pandemic, Jinmailang introduced MYbank and its “310 model” to help them prepare for recovery in the post-COVID-19 era. Using key operational data provided by Jinmailang, such as order fulfillment and logistics records, MYbank was able to extend lines of credit to SME distributors so that they can use the short-term funding to restock from the food producer. This also served to ensure the funding will be used solely for economic recovery purposes.

MYbank has implemented a series of measures to help small and micro business owners overcome the economic impact of the COVID-19 pandemic, including waiving or lowering interest rates. In March, MYbank partnered with 100 banks to launch the “Contactless Loans” initiative to support SMEs as they resume operations and overcome the impact of COVID-19. According to the China Banking Association, the initiative had served over 10 million SMEs and extended loans totaling RMB 400 billion as of the end of April 2020.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bell Wang
E: yixing.wl@antfin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye